Neoantigen
Latest round
- Angel
Last raised
- Jun 2016
Total raised
- Undisclosed
Investors
- 3
About Neoantigen
Established in 2016 and based in Hangzhou, China, Neoantigen is a biotechnology company that engaged in the research and development of personalized tumor vaccines. Prof. Shuqing Chen, the founder and chairman of the company, was the technical Advisor to the President of Qianyuan Pharmaceutical. The company partners with Innovent, Virogin Biotech and many high schools such as Zhejiang University. The company focuses on the research and development of various types of personalized immunotherapy products based on neoantigens. The company also built industry chain of nascent antigen-new drug research and development platforms including artificial intelligence automated identification and optimization system, in vitro verification cell platform, personalized peptide drug preparation and quality control system. The company research team comes from Zhejiang University, Harvard University in the United States, UBC University in Canada and etc.
Who invested in Neoantigen
3 investors across 1 round
See all investors in Neoantigen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Angel
Jun 1, 2016
Amount
Undisclosed
Investors
Questions about Neoantigen
Who invested in Neoantigen?
Neoantigen has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Neoantigen raised?
Neoantigen has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Neoantigen last raise money?
Neoantigen's most recent round on record is a Angel, in Jun 2016.
What does Neoantigen do?
Established in 2016 and based in Hangzhou, China, Neoantigen is a biotechnology company that engaged in the research and development of personalized tumor vaccines.
Where is Neoantigen headquartered?
Neoantigen is headquartered in Hangzhou, China.
Which VCs invest in companies like Neoantigen?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back biotechnology companies at Neoantigen's stage. Their profiles are linked below.
VCs backing biotechnology startups at Angel
Raising like Neoantigen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.